Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in Long QT Syndrome Type 3
NCT01728025Phase 2Unknown
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Oct 2012
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranolazine in Long QT Syndrome Type 3 (LQT3), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Number of participants with syncope and/or documented ventricular arrhythmia at 5 years. Status: unknown.
02
Drugs
ranolazine
03
Conditions
Long QT Syndrome Type 3 (LQT3)
Beyond the preview
Go deeper on NCT01728025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01728025.